Gain Therapeutics names Jeanette Weidner VP Finance and principal financial officer
Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance, effective October 28, 2026, and she will also serve as principal financial officer and principal accounting officer. The filing sets out her employment terms, including a $275,000 base salary, a target bonus of 35% of salary, and an option for 130,000 shares, which matter to shareholders because they define the compensation and severance commitments the company is taking on.
Key points
- Appointment effective October 28, 2026; appointed on October 22, 2026
- Annual base salary of $275,000 with an initial target bonus of 35% of base salary
- Option to purchase up to 130,000 shares under the 2022 Equity Incentive Plan, vesting over four years
- Severance of six months' base salary, or twelve months' base salary plus other benefits if terminated within twelve months after a change of control
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.